Congratulations to our client, RoslinCT, who entered into a business combination agreement with Lykan Bioscience, the US based innovative CDMO focused on cell-based therapies. RoslinCT, a portfolio company of GHO Capital Partners LLP, and Lykan Bioscience, a portfolio company of WindRose Health Investors, combine to create a leading global advanced cell therapy CDMO. https://bit.ly/3JxMrU4 #AMon #DueDiligence #GlobalCDMO #Bioscience #CellTherapies
